EyePoint’s Duravyu falls short to Eylea in Phase III trial
GlobalData highlighted EyePoint’s Duravyu as a notable drug set to enter the wet AMD market by 2034.
GlobalData highlighted EyePoint’s Duravyu as a notable drug set to enter the wet AMD market by 2034.
With regulatory conditions tightening around climate impact and environmental persistence of medical propellants, HFA-152a is a practical route to maintain clinical performance, patient outcomes and supply continuity of inhalers. However,...
The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms,...
Pharma Technology Focus is our digital magazine, free to read online on all devices. Click the magazine cover to read the latest issue. You can subscribe for free to have each new issue delivered to your inbox.
TrialAssure selected as EMA’s official clinical trial anonymisation partner
ASCO26: AI innovations show promise in reducing the oncology RWD burden
Keeping pace with generative AI in pharmaceutical and healthcare organisations
How wearables can unlock their full potential in clinical research